Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 11, 2017

View Archived Issues

Synthon opens phase III trial of SYD-985 in HER2-positive advanced breast cancer

Everfront studies Cerebraca wafer with adjuvant temozolomide in recurrent high-grade glioma

Patient recruitment ongoing in phase I trial of TRK-750

Adverum Biotechnologies begins phase I/II ADVANCE trial in alpha-1 antitrypsin deficiency

FDA grants fast track designation for CA-008 as treatment of postsurgical pain

Positive topline results from phase II study of SAGE-217 in patients with MDD

MeiraGTx drug for LCA2 obtains FDA rare pediatric disease designation

CCL-20 S64C demonstrates efficacy in IL-23-dependent mouse model of psoriasis

FDA gives fast track designation to Aptinyx's NYX-783

AVEO Oncology gives update on tivozanib and ficlatuzumab studies

Xoma licenses XOMA-358 to Rezolute

Phase IIb study of eryaspase for AML does not meet primary endpoint

GlaxoSmithKline patents BRD4 inhibitors

Roche presents new EAAT3 inhibitors for glaucoma

FDA grants fast track designation to Rhizen's RP-6530 for relapsed/refractory PTCL

Enanta Pharmaceuticals discovers bile acid receptor agonists

Merck & Co. divulges new FFA4 receptor agonists

Novel CBP inhibitors presented by Genentech and Constellation Pharmaceuticals

Metacrine closes series B financing to advance MET-409

FDA approves Sunovion's Lonhala Magnair

Ayala Pharmaceuticals obtains rights to two BMS compounds

IDMC recommends continuation of phase IIa study of milciclib in HCC

OG-L002 shows promising in vivo results for the treatment of sickle cell disease

GT Biopharma initiates phase I study of GTP-004 for the treatment of myasthenia gravis

Pieris Pharmaceuticals cleared to begin clinical testing of PRS-060

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...